B of A Securities Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Brian Cheng maintains a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $40 to $43.
September 08, 2023 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Apellis Pharmaceuticals' price target has been raised from $40 to $43 by B of A Securities, while maintaining a Neutral rating.
The news is directly about Apellis Pharmaceuticals. The raised price target indicates a positive outlook, but the maintained Neutral rating suggests that the analyst does not see significant upside potential in the short term. This could lead to a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100